Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant erythropoietin for severe COVID-19 with anemia
IRCT20200509047364N1Phase 2Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-blind trial of erythropoietin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoints: Patient clinical symptoms, Laboratory examinations of patients and 1 more. Started Jun 2020; status: completed.
02
Drugs
erythropoietin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200509047364N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200509047364N1.